This week ARDAT project members met at the University of Sheffield to celebrate its general assembly. The ARDAT project aims to develop tools and provide data to fill knowledge gaps in the areas of immunology and gene therapy vector metabolism as well as identifying areas for regulatory harmonisation. The overall objective of the project is to accelerate the research and development of Advanced Therapy Medicinal Products (ATMPs) so that safer and more effective life-changing therapies can reach patients as soon as possible.
ASPHALION is a proud ARDAT partner and co-lead of the regulatory work package, which aims to engage regulators and support recommendations for regulatory harmonisation. ASPHALION experts Christopher Mann and Jon Giblin attended the meeting, with Christopher providing a summary of the progress in the past year and ongoing tasks.
A big thank you to the University of Sheffield for hosting a dynamic and exciting meeting, and to all the presenters who showcased the great progress made in the past year.
The ARDAT project is funded by the Innovative Health Initiative (IHI), an EU public-private partnership. It represents a collaboration between academia, Small Medium Enterprises (SMEs) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Need help in your EU-funded projects or regulatory endeavours? Contact us at: [email protected]
